NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

These two quotes below from Bioselect investor I will take exception to that is amply demonstrated by these two Microcap emerging Biotechs in CANCER arena that were PUMMELED TODAY:

The market is artificially depressed, as it often is, to communicate exactly that... let’s the players do their thing with less fear... just a few big players change their personal evaluations, and probability changes. But that can’t easily happen on the OTC. So

Granted, there is less room for errors, basically none, at the bottom. That’s why this side of the market constantly overreacts, which creates massive volatility and lots of room for profits and losses

I will take exception to the above in that is amply demonstrated by these two Microcap emerging Biotechs that were PUMMELED TODAY that ALREADY were PULVERIZED re BigCharts:

CLSN from $9500/shr to $1:
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=Clsn&insttype=&freq=2&show=&time=20

In pH 3 Liver Cancer:

Celsion craters 65% on dim hopes for ThermoDox in liver cancer
https://seekingalpha.com/news/3590562-celsion-craters-65-on-dim-hopes-for-thermodox-in-liver-cancer

Celsion (NASDAQ:CLSN) plummets 65% premarket on robust volume in reaction to its announcement that the independent Data Monitoring Committee (DMC) has recommended the termination of the Phase 3 OPTIMA study evaluating ThermoDox, combined with radiofrequency ablation (RFA), in patients with hepatocellular carcinoma or primary liver cancer.
The DMC made its recommendation based on a pre-planned interim safety and efficacy analysis that showed the study was unlikely to achieve the primary endpoint after exceeding a futility threshold value.

Gritstone Oncology down 32% on cancer vaccinedatahttps://seekingalpha.com/news/3590559-gritstone-oncology-down-32-on-cancer-vaccine-data

Thinly traded micro cap Gritstone Oncology (NASDAQ:GRTS) slumps 32% premarket on increased volume on the heels of its presentation of interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen therapeutic vaccine candidates, respectively, in patients with solid tumors.
Investors appear to have expected more significant treatment effects.
Phase 2 studies are next up

SAME for BigChart on GRTS from low $30's to $4. :
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=Grts&insttype=&freq=2&show=&time=20

DIFFERENT STROKES FOR DIFFERENT FOLKS